

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Levamisole Hydrochloride (8%) Liquid Formulation

Other means of identification : COOPERS NILVERM LV ORAL WORMER (36152)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Veterinary product

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Drynam Road
K67 P263 Dublin, Ireland

Telephone : +1-908-740-4000

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2 H361d: Suspected of damaging the unborn child.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

Hazard statements : H361d Suspected of damaging the unborn child.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

Precautionary statements : **Prevention:**

P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

levamisole hydrochloride

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
levamisole hydrochloride	16595-80-5 240-654-6	Acute Tox. 3; H301 Repr. 2; H361d STOT RE 2; H373 (Blood, Testis) Aquatic Chronic 3; H412	>= 3 - < 10
Citric acid	77-92-9 201-069-1 607-750-00-3	Eye Irrit. 2; H319 STOT SE 3; H335	>= 1 - < 10

For explanation of abbreviations see section 16.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | | |
|----------------------------|---|---|
| General advice | : | In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : | First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : | If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : | In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : | Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists. |
| If swallowed | : | If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | | |
|-------|---|---|
| Risks | : | Suspected of damaging the unborn child. |
|-------|---|---|

4.3 Indication of any immediate medical attention and special treatment needed

- | | | |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|

SECTION 5: Firefighting measures

5.1 Extinguishing media

- | | | |
|--------------------------------|---|--|
| Suitable extinguishing media | : | Water spray
Alcohol-resistant foam
Carbon dioxide (CO ₂)
Dry chemical |
| Unsuitable extinguishing media | : | None known. |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|--|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Gases |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
levamisole hydrochloride	16595-80-5	TWA	20 µg/m3 (OEB 3)	Internal

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version 4.0 Revision Date: 14.04.2025 SDS Number: 10849426-00007 Date of last issue: 28.09.2024
Date of first issue: 09.09.2022

Further information: Skin				
		Wipe limit	200 µg/100 cm ²	Internal

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Citric acid	Fresh water	0.44 mg/l
	Marine water	0.044 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	34.6 mg/kg dry weight (d.w.)
	Marine sediment	3.46 mg/kg dry weight (d.w.)
	Soil	33.1 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	: liquid
Colour	: clear yellow
Odour	: No data available
Odour Threshold	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Flash point	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
pH	: No data available
Viscosity	
Viscosity, kinematic	: No data available
Solubility(ies)	
Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Vapour pressure	: No data available
Relative density	: No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

Density : No data available

Relative vapour density : No data available

Particle characteristics
Particle size : Not applicable

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure :
Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

|| Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

levamisole hydrochloride:

Acute oral toxicity : LD50 (Rat): 180 mg/kg
LD50 (Mouse): 223 mg/kg
LD50 (Rabbit): 458 mg/kg
Acute inhalation toxicity : Remarks: No data available
Acute dermal toxicity : Remarks: No data available

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

levamisole hydrochloride:

Remarks : No data available

Citric acid:

Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

levamisole hydrochloride:

Remarks : No data available

Citric acid:

Species : Rabbit

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

Method	: OECD Test Guideline 405
Result	: Irritation to eyes, reversing within 21 days

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

levamisole hydrochloride:

Remarks	: No data available
---------	---------------------

Germ cell mutagenicity

Not classified based on available information.

Components:

levamisole hydrochloride:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosome aberration test in vitro Result: negative

Citric acid:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: in vitro micronucleus test Result: positive
	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Ingestion Result: negative

Carcinogenicity

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

Components:

levamisole hydrochloride:

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 80 mg/kg body weight
Remarks	: No significant adverse effects were reported

Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 40 mg/kg body weight
Remarks	: No significant adverse effects were reported

Reproductive toxicity

|| Suspected of damaging the unborn child.

Components:

levamisole hydrochloride:

Effects on fertility	: Test Type: Three-generation reproduction toxicity study Species: Rat Application Route: Oral Result: No significant adverse effects were reported
----------------------	--

Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: NOAEL: 20 mg/kg body weight Result: Fetotoxicity
-------------------------------	--

	: Test Type: Embryo-foetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 40 mg/kg body weight Result: Fetotoxicity
--	---

Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.
------------------------------------	---

Citric acid:

Effects on foetal development	: Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Ingestion Result: negative
-------------------------------	---

STOT - single exposure

|| Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

Components:

Citric acid:

Assessment : May cause respiratory irritation.

STOT - repeated exposure

Not classified based on available information.

Components:

levamisole hydrochloride:

Target Organs : Blood, Testis
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

levamisole hydrochloride:

Species : Rat
NOAEL : 2.5 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Testis

Species : Dog
LOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 18 Months
Target Organs : Blood

Species : Dog
LOAEL : 40 mg/kg
Application Route : Oral
Exposure time : 3 Months

Citric acid:

Species : Rat
NOAEL : 4,000 mg/kg
LOAEL : 8,000 mg/kg
Application Route : Ingestion
Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

11.2 Information on other hazards

Endocrine disrupting properties

|||Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

levamisole hydrochloride:

|||Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

SECTION 12: Ecological information

12.1 Toxicity

Components:

levamisole hydrochloride:

|||Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

|||Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Citric acid:

|||Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
Exposure time: 96 h

|||Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l
Exposure time: 24 h

12.2 Persistence and degradability

Components:

Citric acid:

|||Biodegradability : Result: Readily biodegradable.
Biodegradation: 97 %
Exposure time: 28 d

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

||

Method: OECD Test Guideline 301B

12.3 Bioaccumulative potential

Components:

Citric acid:

|| Partition coefficient: n- : log Pow: -1.72
octanol/water

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks	:	Not applicable for product as supplied.
---------	---	---

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

: Conditions of restriction for the following entries should be considered:
Number on list 3

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

Regulation (EU) No 2024/590 on substances that deplete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollutants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals

REACH - List of substances subject to authorisation (Annex XIV)

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.
Not applicable

: Not applicable

: Not applicable

: Not applicable

: Not applicable

: Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H301 : Toxic if swallowed.
H319 : Causes serious eye irritation.
H335 : May cause respiratory irritation.
H361d : Suspected of damaging the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.
H412 : Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure
STOT SE : Specific target organ toxicity - single exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure-Activity Relationship

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Levamisole Hydrochloride (8%) Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.0	14.04.2025	10849426-00007	Date of first issue: 09.09.2022

tative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Repr. 2

H361d

Classification procedure:

Calculation method

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN